Sarissa Capital Management LP Intercept Pharmaceuticals, Inc. Transaction History

Sarissa Capital Management LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$12.99 - $20.47 $12,340 - $19,446	-950 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$24.48 - $42.47 $29.4 Million - $51 Million	-1,200,050 Reduced 99.92%	950 $23,000
Q2 2020 Aug 14, 2020	BUY	$46.7 - $92.04 $2.15 Million - $4.23 Million	46,000 Added 3.98%	1,201,000 $57.5 Million
Q1 2020 May 15, 2020	BUY	$48.35 - $118.68 $14.3 Million - $35 Million	295,000 Added 34.3%	1,155,000 $72.7 Million
Q4 2019 Feb 14, 2020	BUY	$57.36 - $124.1 $516,240 - $1.12 Million	9,000 Added 1.06%	860,000 $107 Million
Q3 2019 Nov 14, 2019	BUY	$58.69 - $80.46 $5.52 Million - $7.56 Million	94,000 Added 12.42%	851,000 $56.5 Million
Q2 2019 Aug 14, 2019	BUY	$77.77 - $120.68 $34 Million - $52.7 Million	437,000 Added 136.56%	757,000 $60.2 Million
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $24.4 Million - $32.1 Million	266,000 Added 492.59%	320,000 $35.8 Million
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $17.5 Million - $25.7 Million	-203,500 Reduced 79.03%	54,000 $5.44 Million
Q3 2018 Nov 14, 2018	SELL	$88.49 - $127.55 $33.4 Million - $48.2 Million	-377,800 Reduced 59.47%	257,500 $32.5 Million
Q1 2018 May 15, 2018	BUY	$52.72 - $67.25 $23.9 Million - $30.5 Million	453,000 Added 248.49%	635,300 $39.1 Million
Q4 2017 Feb 14, 2018	BUY	$58.2 - $72.76 $10.6 Million - $13.3 Million	182,300	182,300 $10.6 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Sarissa Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Sarissa Capital Management LP with notifications on news.